NEUROLOGY ASIA, cilt.25, sa.1, ss.85-86, 2020 (SCI-Expanded)
Nusinersen is a novel therapy for spinal muscular atrophy (SMA) type 1. Thus, the adverse reactions of the therapy have not been well established. We present here a 5-months old boy with SMA type 1, who developed hyponatremia after a single dose of nursinersen which has been rarely reported previously.